Stock Track | Evotec SE Plunges 9.57% Pre-market on Q3 Earnings Miss and Asset Sale

Stock Track11-05

Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday following the release of disappointing third-quarter results and news of an asset sale. The German biotech company faced a double whammy of negative news, triggering a significant sell-off among investors.

Evotec reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% decline from the same period last year. More concerning was the company's revenue, which came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by a substantial 19.26%. This also marked a 5.71% decrease from the previous year's sales, indicating potential challenges in the company's core business operations.

Adding to investor concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While the company framed this as a successful transaction, it may have raised questions about Evotec's strategic direction and future growth prospects. The combination of weak quarterly results and the divestment of assets appears to have shaken investor confidence, leading to the sharp pre-market decline in Evotec's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157524551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157524551","market":"sg","top_or_hot":-1,"title":"Stock Track | Evotec SE Plunges 9.57% Pre-market on Q3 Earnings Miss and Asset Sale","media":"Stock Track","content":"<p>Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday following the release of disappointing third-quarter results and news of an asset sale. The German biotech company faced a double whammy of negative news, triggering a significant sell-off among investors.</p>\n\n<p>Evotec reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% decline from the same period last year. More concerning was the company's revenue, which came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by a substantial 19.26%. This also marked a 5.71% decrease from the previous year's sales, indicating potential challenges in the company's core business operations.</p>\n\n<p>Adding to investor concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While the company framed this as a successful transaction, it may have raised questions about Evotec's strategic direction and future growth prospects. The combination of weak quarterly results and the divestment of assets appears to have shaken investor confidence, leading to the sharp pre-market decline in Evotec's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evotec SE Plunges 9.57% Pre-market on Q3 Earnings Miss and Asset Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evotec SE Plunges 9.57% Pre-market on Q3 Earnings Miss and Asset Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday following the release of disappointing third-quarter results and news of an asset sale. The German biotech company faced a double whammy of negative news, triggering a significant sell-off among investors.</p>\n\n<p>Evotec reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% decline from the same period last year. More concerning was the company's revenue, which came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by a substantial 19.26%. This also marked a 5.71% decrease from the previous year's sales, indicating potential challenges in the company's core business operations.</p>\n\n<p>Adding to investor concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While the company framed this as a successful transaction, it may have raised questions about Evotec's strategic direction and future growth prospects. The combination of weak quarterly results and the divestment of assets appears to have shaken investor confidence, leading to the sharp pre-market decline in Evotec's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVO","symbol_name":"Evotec SE","start_time":0,"source_url":"","article_id":"1157524551","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157524551","pubTimestamp":1762333585,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday following the release of disappointing third-quarter results and news of an asset sale. The German biotech company faced a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVO":"Evotec SE"},"translate_title":"股票追踪|Evotec SE盘前暴跌9.57%因第三季度盈利未达预期和资产出售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVO":1},"content_text":"Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday following the release of disappointing third-quarter results and news of an asset sale. The German biotech company faced a double whammy of negative news, triggering a significant sell-off among investors.\nEvotec reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% decline from the same period last year. More concerning was the company's revenue, which came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by a substantial 19.26%. This also marked a 5.71% decrease from the previous year's sales, indicating potential challenges in the company's core business operations.\nAdding to investor concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While the company framed this as a successful transaction, it may have raised questions about Evotec's strategic direction and future growth prospects. The combination of weak quarterly results and the divestment of assets appears to have shaken investor confidence, leading to the sharp pre-market decline in Evotec's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157524551","isCrawlerRequest":true}